Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to establish national accountability for improving brain cancer outcomes, including the development of a time sensitive clinical trials pipeline; and whether he plans to introduce ring fenced funding to support delivery in that area.

The National Cancer Plan, published on the 4 February 2026, sets out several commitments and ambitions, to be delivered within the next 10 years. The role of the reformed National Cancer Board will be to support and monitor the delivery of the commitments and ambitions and provide regular updates to ministers.

To hold us accountable across these commitments, and to drive forward progress for rare cancer patients, we will appoint a National Clinical Lead for Rare Cancers, who will bring accountability, to oversee performance against the rare cancers commitments in the plan, including for brain cancer. They will sit on the reformed National Cancer Board and will play an important advisory role in supporting and monitoring delivery of the commitments set out in the National Cancer Plan. This role is separate to the National Specialty Lead for Rare Cancers appointed under the Rare Cancers Act 2026, which will be based in the National Institute for Health and Care Research’s (NIHR) Research Delivery Network and will support research delivery for rare cancers.

The Department invests over £1.8 billion each year on research through the NIHR. Cancer is a major area of NIHR spending at £141.6 million in 2024/25, reflecting its high priority.

We are committed to furthering our investment in brain cancer research and have already taken steps to stimulate scientific progress and build scientific capacity to do research on brain cancer. For example, in December 2025 an initial NIHR Brain Tumour Research Consortium award of £13.7 million was confirmed. In January 2026, the NIHR announced further investment of a minimum of £11.7 million in the Consortium through the funding of work packages. This brings the Consortium funding to over £25 million over its lifespan.

It is not the usual process of the NIHR to ringfence funds for research into specific conditions. The NIHR welcomes funding applications for research into any aspect of human health and care, including brain cancer. Our approach to funding research is through open and fair competition and peer review to ensure that the highest-quality proposals, most likely to deliver real impact for patients, are funded without imposing financial targets or limits.

The Department is committed to ensuring that all patients, including those with brain cancer, have access to cutting-edge clinical trials, and innovative, lifesaving treatments through the NIHR.

As set out in the Life Sciences Sector Plan and reinforced in the 10-Year Health Plan for England, the Department is committed to cutting the current time it takes to get a clinical trial set up, to under 150 days, with the aim of increasing access to patients and making the United Kingdom a world leader in clinical trials. The Life Sciences Sector Plan and the 10-Year Health Plan for England are available at the following two links respectively:

https://www.gov.uk/government/publications/life-sciences-sector-plan

https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-future

Data published in April 2026 shows that the median average set-up time for commercial interventional trials in the first six months of 2025/26 was 122 days, down from 169 days in the same period last year.